<?xml version="1.0" encoding="UTF-8"?>
<p>Another INSTI, cabotegravir (CAB), is the newest drug that is being developed as a long-acting injectable for monthly or quarterly administration and as an oral tablet for daily use for the treatment and prevention of HIV-1 infection, and it is currently in the late phase of clinical trials [
 <xref rid="B8-viruses-12-00838" ref-type="bibr">8</xref>,
 <xref rid="B15-viruses-12-00838" ref-type="bibr">15</xref>]. At present, a long-acting regimen with CAB has been approved by Health Canada. Recently, the FLAIR clinical trial showed that a long-acting regimen of CAB and rilpivirine (RPV) is noninferior for HIV maintenance therapy compared to DTG, abacavir (ABC), and lamivudine (3TC) in na√Øve patients. However, 3 participants experienced virological failure. Interestingly, these patients were all from Russia and had an HIV infection with subtype A and the L74I mutation before the treatment initiation [
 <xref rid="B15-viruses-12-00838" ref-type="bibr">15</xref>]. The efficacy outcomes in this study were similar to those of the ATLAS study, which had 2 treatment experience participants with the L74I mutation from the Russian Federation with virological failure after therapy containing CAB [
 <xref rid="B16-viruses-12-00838" ref-type="bibr">16</xref>].
</p>
